The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of low-dose peginterferon alfa-2b antiangiogenic therapy in patients with metastatic melanoma overexpressing basic fibroblast growth factor: An Eastern Cooperative Oncology Group study (E2602).
Ronald S. Go
No relevant relationships to disclose
Sandra J. Lee
No relevant relationships to disclose
Donghoon Shin
No relevant relationships to disclose
Steven M Callister
No relevant relationships to disclose
Dean A Jobe
No relevant relationships to disclose
Robert Martin Conry
No relevant relationships to disclose
Ahmad A. Tarhini
No relevant relationships to disclose
John M. Kirkwood
No relevant relationships to disclose